We are live on ! Find out more
IMNM icon

Immunome

29 hedge funds and large institutions have $41.1M invested in Immunome in 2021 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 7

2.3% more ownership

Funds ownership: 17.91%20.21% (+2.3%)

6% less funds holding

Funds holding: 3129 (-2)

15% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 13

36% less capital invested

Capital invested by funds: $64.6M → $41.1M (-$23.5M)

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $5K

Holders
29
Holders Change
-2
Holders Change %
-6.45%
% of All Funds
0.5%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
11
Increased
8
Reduced
7
Closed
13
Calls
Puts
$5K
Net Calls
-$5K
Net Calls Change
-$5K

IMNM Hedge Fund Activity: Q2 2021 in Review

29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Immunome (IMNM) for Q2 2021, worth a combined $41.1M — down 36% from $64.6M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of IMNM and 11 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 8 added.

The largest buyer was Prentice Capital Management, adding an estimated $4.09M. The largest seller was BlackRock, cutting an estimated $1.99M.

  • 29 institutional investors held Immunome (IMNM) as of Q2 2021, down from 31 in Q1 2021.
  • Funds reported $41.1M of Immunome stock for Q2 2021, down 36% quarter-over-quarter.
  • 11 funds opened new Immunome positions in Q2 2021 and 13 closed out, a net change of -2 holders.
  • The largest Immunome buyer in Q2 2021 was Prentice Capital Management, an estimated $4.09M added.
  • The largest Immunome seller in Q2 2021 was BlackRock, an estimated $1.99M sold.

Based on aggregated 13F filings for Q2 2021.